Skip to main content
. 2017 Aug 7;8(47):82897–82909. doi: 10.18632/oncotarget.19970

Figure 2. Comparative antineoplastic activity of crenolanib in mutant-kinase and kinase-unspecific cell models.

Figure 2

Dilution series of crenolanib to treat FLT3 ITD (MOLM14, A), FIP1L1/PDGFRA (EOL-1, B) or BCR/ABLA (K562, C) positive leukemia cell lines were set up to assess for induction of apoptosis. In addition, tyrosine kinase-unspecific leukemia cell lines Jurkat (D) and HL60 (E) were treated to assess non-target toxicity of crenolanib, which is defined >1000 nM. One-way ANOVA and Tukey’s honestly significant difference (HSD) tests are provided. Values in black indicate significance compared to the untreated controls.